Pharmaceutical composition
The combination of naproxen and acetaminophen with specific basic compounds in the pharmaceutical composition addresses the stability issue, achieving enhanced storage stability and reduced discoloration, thereby maintaining the effectiveness of the medication.
Patent Information
- Application Number
- PCT/JP2024/016951
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2024-05-07
- Publication Date
- 2024-11-14
AI Technical Summary
The stability of pharmaceutical compositions containing naproxen and acetaminophen is affected by interactions that cause changes in appearance over time, leading to potential discoloration, which is not effectively addressed by existing formulations.
A pharmaceutical composition combining naproxen or its salt with acetaminophen, along with specific basic compounds such as magnesium silicate, magnesium oxide, synthetic hydrotalcite, aluminum hydroxide gel, or glycine, in specific mass ratios, to inhibit discoloration and maintain storage stability.
The composition effectively suppresses changes in appearance, ensuring excellent storage stability and maintaining the medicinal efficacy of naproxen and acetaminophen, as demonstrated by evaluations showing reduced discoloration scores.
Smart Images

Figure JPOXMLDOC01-APPB-T000001 
Figure JPOXMLDOC01-APPB-T000002
Abstract
Description
Pharmaceutical Composition
[0001] The present invention relates to a pharmaceutical composition containing naproxen or a salt thereof.
[0002] Naproxen is a propionic acid-based nonsteroidal antipyretic, analgesic, and anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic effects by inhibiting the biosynthesis of prostaglandins, which cause fever and inflammation (Non-Patent Document 1). Currently, NSAIDs have relatively few side effects and are widely used not only in prescription medicines but also in over-the-counter (OTC) medicines as the main ingredients of antipyretic analgesics and cold remedies. Therefore, naproxen is expected to be used in over-the-counter medicines. Because naproxen has the above-mentioned pharmacological effects, efforts are being made to further enhance the efficacy of naproxen itself. For example, it has been reported that combining naproxen with specific pharmaceutical ingredients enhances its antipyretic, analgesic, and anti-inflammatory effects (Patent Documents 1 and 2). It has also been reported that combining naproxen with basic compounds such as antacids improves disintegration properties (Patent Document 3). However, it is unknown whether a pharmaceutical composition containing naproxen and acetaminophen would exhibit interactions that directly affect the stability of the formulation.
[0003] JP 2018-76305 A JP 2018-76306 A JP 2018-76310 A
[0004] Nikesan Tablets 100mg Interview Form
[0005] The present inventors combined naproxen with acetaminophen, an antipyretic and analgesic ingredient, and confirmed the storage stability of the preparation, and surprisingly discovered that the appearance changed over time.
[0006] Therefore, an object of the present invention is to provide a pharmaceutical composition which contains naproxen or a salt thereof and acetaminophen or a salt thereof and has excellent storage stability.
[0007] The present inventors have conducted various studies to solve the above problems and have found that the change in appearance can be suppressed by blending a specific component, thereby completing the present invention.
[0008] That is, the present invention provides: (1) a pharmaceutical composition comprising (A) naproxen or a salt thereof, (B) acetaminophen or a salt thereof, and (C) at least one selected from the group consisting of the following (c1) and (c2): (c1) at least one basic compound selected from the group consisting of magnesium silicate, magnesium oxide, magnesium carbonate, synthetic hydrotalcite, aluminum hydroxide gel, and magnesium aluminometasilicate (c2) glycine or a salt thereof, (2) the pharmaceutical composition according to (1), wherein the content ratio of component (A) to component (B) is 0.125 to 150 parts by mass, preferably 0.25 to 9 parts by mass, of component (B) per part by mass of component (A), (3) the pharmaceutical composition according to (1) or (2), wherein the content of component (C) is 0.01 to 2 parts by mass per part by mass of the total content of component (A) and component (B), (4) the pharmaceutical composition according to any of (1) to (3), wherein the pharmaceutical composition is a solid preparation, (5) A method for inhibiting discoloration of a pharmaceutical composition containing (A) naproxen or a salt thereof and (B) acetaminophen or a salt thereof, characterized in that the composition contains (C) at least one selected from the group consisting of the following (c1) and (c2): (c1) at least one basic compound selected from the group consisting of magnesium silicate, magnesium oxide, magnesium carbonate, synthetic hydrotalcite, aluminum hydroxide gel, and magnesium aluminometasilicate; and (c2) glycine or a salt thereof, but is not limited to these.
[0009] According to the present invention, it is possible to provide a pharmaceutical composition containing naproxen or a salt thereof and acetaminophen or a salt thereof, which has excellent storage stability.
[0010] The pharmaceutical composition of the present invention containing naproxen or a salt thereof will be described in detail below. For clarity, the compounds and salts thereof referred to in the present invention may be in the form of solvates with water, alcohol, etc.
[0011] <Component (A)> Component (A) in the pharmaceutical composition of the present invention includes not only naproxen but also pharmaceutically acceptable salts of naproxen, and solvates with water, alcohol, etc. These are known compounds and can be produced by known methods, or commercially available products can be used. In the present invention, naproxen is preferred as naproxen or a salt thereof. The naproxen used in the pharmaceutical composition of the present invention has the chemical name (2S)-2-(6-methoxynaphthalen-2-yl)propanoic acid and the molecular formula C 14 H 14 O 3 and has a molecular weight of 230.26. Naproxen is a well-known anti-inflammatory analgesic agent of the propionic acid group, a nonsteroidal anti-inflammatory analgesic, and is widely used for the purposes of anti-inflammation, analgesia, and fever reduction in diseases such as rheumatoid arthritis, osteoarthritis, gout attacks, ankylosing spondylitis, lower back pain, periarthritis of the shoulder, cervicobrachial syndrome, tendonitis / tendonitis, dysmenorrhea, and shingles, as well as for anti-inflammation and analgesia after trauma and surgery, and after tooth extraction and minor surgery in the fields of dentistry and oral surgery. The naproxen salt in the pharmaceutical composition of the present invention may be any pharmaceutically acceptable salt, and examples thereof include sodium salt, potassium salt, ammonium salt, meglumine salt, Tris salt, and salts of basic amino acids. The content of naproxen or a salt thereof in the pharmaceutical composition of the present invention is not particularly limited as long as it is an amount that exhibits its medicinal efficacy, and may be appropriately determined depending on the gender, age, symptoms, etc. of the recipient. For adults aged 15 years or older, the daily dose is usually 10 to 1200 mg, preferably 15 to 900 mg, and more preferably 20 to 600 mg, and the single dose is preferably 100 to 200 mg. The number of times of administration per day is appropriately selected from 1 to 3 times. Furthermore, the content of naproxen or a salt thereof is preferably 1 to 60% by mass, more preferably 5 to 50% by mass, even more preferably 10 to 50% by mass, and particularly preferably 10 to 40% by mass, based on the total mass of the pharmaceutical composition.
[0012] <Component (B)> The acetaminophen in the pharmaceutical composition of the present invention is N-(4-hydroxyphenyl)acetamide, an antipyretic and analgesic ingredient. While the acetaminophen of the present invention is not particularly limited, it is preferably one that complies with the Japanese Pharmacopoeia. Acetaminophen is also known as paracetamol. Acetaminophen and its salts can be used, either singly or in appropriate combinations of two or more. The salt of acetaminophen in the pharmaceutical composition of the present invention may be any pharmaceutically acceptable salt, including, for example, sodium salt, potassium salt, ammonium salt, meglumine salt, Tris salt, and salts of basic amino acids. The content of acetaminophen or its salt in the pharmaceutical composition of the present invention is not particularly limited as long as it is an amount that exhibits its medicinal efficacy, but may be appropriately determined depending on the gender, age, symptoms, etc. of the recipient. The daily dose for adults aged 15 years or older is preferably 150 to 1500 mg, more preferably 150 to 1200 mg, and even more preferably 150 to 900 mg. The number of daily doses is appropriately selected from 1 to 3 times. Furthermore, the content of acetaminophen or a salt thereof relative to the total mass of the pharmaceutical composition is preferably 5 to 80% by mass, more preferably 5 to 75% by mass, even more preferably 5 to 70% by mass, and particularly preferably 9 to 60% by mass. The total content of component (A) and component (B) contained in the pharmaceutical composition of the present invention is preferably 15 to 90% by mass, more preferably 15 to 80% by mass, and even more preferably 25 to 75% by mass. The content ratio of component (A) to component (B) is not particularly limited, but is preferably 0.125 to 150 parts by mass, more preferably 0.25 to 9 parts by mass, more preferably 0.25 to 3 parts by mass, even more preferably 0.25 to 2.0 parts by mass, and particularly preferably 0.25 to 1.5 parts by mass, of (B) acetaminophen or a salt thereof per part by mass of (A) naproxen or a salt thereof.
[0013] <Component (C)> When the component (C) is present together with the combination of the component (A) and the component (B), a pharmaceutical composition that is less likely to undergo changes in appearance is obtained.
[0014] The component (C) in the pharmaceutical composition of the present invention is at least one selected from the group consisting of the following (c1) and (c2):
[0015] From the viewpoint of preventing changes in appearance, the content of component (C) is preferably 1 to 80% by mass, and more preferably 3 to 73% by mass, relative to the total mass of the pharmaceutical composition of the present invention. In another aspect, the content of component (C) is preferably 20 to 80% by mass, and more preferably 25 to 73% by mass, relative to the total mass of the pharmaceutical composition of the present invention. Furthermore, from the viewpoint of preventing changes in appearance due to the incorporation of naproxen and acetaminophen, the content of component (C) is preferably 0.1 to 3.0, more preferably 0.3 to 2.7 parts by mass, relative to 1 part by mass of the combined content of components (A) and (B). In another preferred aspect, the content of component (C) is 0.01 to 2 parts by mass, relative to 1 part by mass of the combined content of components (A) and (B).
[0016] (Component c1) Component (c1) is a basic compound selected from magnesium silicate, magnesium oxide, magnesium carbonate, synthetic hydrotalcite, (dried) aluminum hydroxide gel, and magnesium aluminometasilicate. The effect of inhibiting appearance change is not observed with other basic compounds such as calcium hydrogen phosphate, magnesium hydroxide, and synthetic aluminum silicate, and is an effect unique to the specific component of the present invention. Synthetic hydrotalcite has the composition Mg 6 Al 2 (OH) 16 CO 3 ・4 (H 2 O) is an artificial clay mineral.
[0017] The daily dose (amount) of magnesium silicate in the pharmaceutical composition of the present invention for those aged 15 years or older is not particularly limited, but is preferably 200 to 3,000 mg, and more preferably 600 to 3,000 mg. The content of the magnesium silicate component in the pharmaceutical composition of the present invention is preferably 20 to 80% by mass, more preferably 25 to 70% by mass, and even more preferably 40 to 70% by mass, relative to the total mass of the pharmaceutical composition of the present invention, from the viewpoint of the effect of suppressing appearance change, and is preferably 0.13 to 2.5 parts by mass, more preferably 0.13 to 2 parts by mass, and particularly preferably 0.4 to 2 parts by mass, relative to 1 part by mass of the combined content of components (A) and (B).
[0018] The daily dose (amount) of magnesium oxide in the pharmaceutical composition of the present invention for those aged 15 years or older is not particularly limited, but is preferably 30 to 500 mg, and more preferably 100 to 500 mg. The content of the magnesium oxide component in the pharmaceutical composition of the present invention is preferably 10 to 50% by mass, more preferably 15 to 40% by mass, and even more preferably 20 to 40% by mass, relative to the total mass of the pharmaceutical composition of the present invention, from the viewpoint of the effect of suppressing appearance change, and is also preferably 0.01 to 1 part by mass, more preferably 0.12 to 0.6 parts by mass, even more preferably 0.2 to 0.6 parts by mass, even more preferably 0.3 to 0.6 parts by mass, and particularly preferably 0.33 to 0.6 parts by mass, relative to 1 part by mass of the combined content of component (A) and component (B).
[0019] The daily dose (amount) of magnesium carbonate in the pharmaceutical composition of the present invention for those aged 15 years or older is not particularly limited, but is preferably 30 to 2,000 mg, more preferably 130 to 2,000 mg, and even more preferably 400 to 2,000 mg. From the viewpoint of the effect of suppressing appearance change, the content of the magnesium carbonate component in the pharmaceutical composition of the present invention is preferably 20 to 80% by mass, more preferably 40 to 60% by mass, relative to the total mass of the pharmaceutical composition of the present invention, and is also preferably 0.09 to 2 parts by mass, more preferably 0.27 to 1.4 parts by mass, and particularly preferably 1.0 to 1.33 parts by mass, relative to 1 part by mass of the combined content of components (A) and (B).
[0020] The daily dose (amount) of synthetic hydrotalcite in the pharmaceutical composition of the present invention for those aged 15 years or older is not particularly limited, but is preferably 260 to 4,000 mg, and more preferably 800 to 4,000 mg. From the viewpoint of the effect of suppressing appearance change, the content of the synthetic hydrotalcite in the pharmaceutical composition of the present invention is preferably 20 to 80% by mass, more preferably 40 to 75% by mass, and even more preferably 50 to 75% by mass, relative to the total mass of the pharmaceutical composition of the present invention, and is preferably 0.18 to 3 parts by mass, more preferably 0.5 to 3 parts by mass, and particularly preferably 1.0 to 2.7 parts by mass, per part by mass of the combined content of component (A) and component (B).
[0021] The aluminum hydroxide gel may be a dried aluminum hydroxide gel. When a dried aluminum hydroxide gel is used, the daily dose (amount blended) of the dried aluminum hydroxide gel in the pharmaceutical composition of the present invention for those aged 15 years or older is not particularly limited, but is preferably 60 to 1000 mg, and more preferably 200 to 1000 mg. When a non-dried aluminum hydroxide gel is used in the present invention, the content of the gel is expressed as the converted amount of dry aluminum hydroxide. It is preferable that this content is the blended amount described above for the dried aluminum hydroxide gel. The dried aluminum hydroxide gel may retain water, such as bound water. The content of aluminum hydroxide gel in the pharmaceutical composition of the present invention is preferably 20 to 80% by mass, and more preferably 40 to 50% by mass, relative to the total mass of the pharmaceutical composition of the present invention, from the viewpoint of the effect of suppressing a change in appearance, and is also preferably 0.07 to 1.5 parts by mass, more preferably 0.33 to 1.0 part by mass, more preferably 0.6 to 1.0 part by mass, and particularly preferably 0.66 to 1.0 part by mass, relative to 1 part by mass of the combined content of component (A) and component (B).
[0022] The daily dose (amount) of magnesium aluminometasilicate in the pharmaceutical composition of the present invention for those aged 15 years or older is not particularly limited, but is preferably 100 to 1500 mg, and more preferably 500 to 1500 mg. The content of magnesium aluminometasilicate in the pharmaceutical composition of the present invention is preferably 10 to 80% by mass, more preferably 10 to 50% by mass, or preferably 20 to 80% by mass, and more preferably 20 to 50% by mass, relative to the total mass of the pharmaceutical composition of the present invention, from the viewpoint of the effect of suppressing appearance change, and is also preferably 0.01 to 3 parts by mass, more preferably 0.05 to 2 parts by mass, and particularly preferably 0.2 to 1.0 part by mass, relative to 1 part by mass of the combined content of component (A) and component (B).
[0023] (Component c2) Component (c2) is glycine or a salt thereof from the viewpoint of suppressing changes in appearance. The daily dose (amount) of glycine or a salt thereof in the pharmaceutical composition of the present invention for those aged 15 years or older is not particularly limited, but is preferably 60 to 900 mg, and more preferably 180 to 900 mg. The content of glycine or a salt thereof in the pharmaceutical composition of the present invention is preferably 1 to 80% by mass, more preferably 3 to 70% by mass, or preferably 20 to 80% by mass, and more preferably 35 to 70% by mass, relative to the total mass of the pharmaceutical composition of the present invention, from the viewpoint of the effect of suppressing changes in appearance. The content of glycine or a salt thereof is also preferably 0.04 to 2.0 parts by mass, more preferably 0.12 to 2.0 parts by mass, and particularly preferably 0.6 to 2.0 parts by mass, relative to 1 part by mass of the combined content of components (A) and (B).
[0024] Although there are no particular limitations on the component (C) of the present invention, it is preferable to use one that is listed in the Japanese Pharmacopoeia, the Japanese Pharmacopoeia Non-Pharmacopoeial Pharmaceutical Standards, etc. The component (C) may be used alone or in appropriate combination of two or more types, and may be a coprecipitate, a coprecipitate product, or a mixed dried gel.
[0025] The pharmaceutical composition of the present invention is generally not particularly limited as long as it is in a dosage form specified in the General Rules for Preparations of the Japanese Pharmacopoeia. From the viewpoint of appearance change, however, tablets, powders, fine granules, granules, pills, and capsules are preferred, with tablets, powders, fine granules, and granules being particularly preferred, and tablets being most preferred. Tablets specified in the General Rules for Preparations of the Japanese Pharmacopoeia include orally disintegrating tablets, chewable tablets, effervescent tablets, dispersible and dissolving tablets, film-coated tablets, sugar-coated tablets, and layered tablets. Furthermore, the tablets may be provided with a score line or a mark or imprint for improved identification. Furthermore, the tablets of the present formulation may be round or irregularly shaped tablets. The present formulation may also be minitablets. When the components (A) and (B) of the present invention are blended so that they are substantially in contact with each other, the degree of appearance change is enhanced, and when the component (C) is added so that they coexist with these components, the appearance change can be effectively suppressed.
[0026] In the pharmaceutical composition of the present invention, preferably, component (A), component (B), and component (C) are substantially in contact with each other. "Component (A), component (B), and component (C) are substantially in contact with each other" refers to a state in which component (A), component (B), and component (C) are mixed together without being physically and / or chemically isolated. However, this does not exclude the incorporation of components other than component (A), component (B), and component (C), and the coexistence of other components is permitted. Furthermore, in the present invention, even when component (A), component (B), and component (C) are contained in separate granules, they can be in a state of substantial contact with each other. However, when they are contained in separate granules and the granules are coated so as not to contact each other, they are not in a state of substantial contact with each other.
[0027] The pharmaceutical composition of the present invention may contain other commonly used active ingredients, excipients, disintegrants, binders, fluidizing agents, lubricants, acidulants, sweeteners, flavoring agents, refreshing agents, colorants, foaming agents, surfactants, plasticizers, coating agents, etc., within qualitative and quantitative ranges that do not impair the effects of the present invention.
[0028] Examples of other active ingredients that can be incorporated into the pharmaceutical composition of the present invention include antipyretics, antihistamines, antitussives, bronchodilators, expectorants, hypnotics and sedatives, vitamins, amino acids, anti-inflammatory agents, gastric mucosa protective agents, herbal medicines, Chinese herbal medicines, caffeines, etc., and the pharmaceutical composition of the present invention may contain one or more kinds selected from the group consisting of these active ingredients.
[0029] Disintegrants that can be incorporated into the pharmaceutical composition of the present invention include low-substituted hydroxypropyl cellulose, sodium starch glycolate, crospovidone, carmellose, carmellose sodium, carmellose calcium, and pregelatinized starch. Binders include hydroxypropyl cellulose, hypromellose, gelatin, pregelatinized starch, polyvinylpyrrolidone, and pullulan. Lubricants include sucrose fatty acid esters, hydrogenated oils, stearic acid, magnesium stearate, and calcium stearate. Flavorings can be incorporated into the present invention to the extent that they do not impair the effects of the present invention. Other antacids, such as calcium hydrogen phosphate, magnesium hydroxide, and synthetic aluminum silicate, can also be incorporated to the extent that they do not impair the effects of the present invention. The pharmaceutical composition of the present invention can be manufactured by conventional methods, and the method is not particularly limited. The tablet of the present invention can be manufactured by mixing the active pharmaceutical ingredient and the above-mentioned additives in an appropriate mixer such as a blender to prepare a mixed powder for tablets, followed by direct compression tableting of the mixed powder, or by compressing granules. Granules can be produced by dry granulation methods (slug method, roller compactor method), wet granulation methods, etc., and although not particularly limited, wet granulation methods are preferred. As wet granulation methods, agitation granulation methods, fluidized bed granulation methods, extrusion granulation methods, tumbling granulation methods, spray granulation methods, etc. may be used, and agitation granulation methods and fluidized bed granulation methods are preferred. As a machine for compressing the powder mixture for tablets or granules of the powder mixture, a single punch tablet press, rotary tablet press, etc. can be used.
[0030] The packaging form of the pharmaceutical composition of the present invention is not particularly limited, but it can be filled into a commercially available container. From the viewpoint of pharmaceutical quality, an airtight container or a sealed container is preferred, and an airtight container is more preferred. Examples of airtight containers include glass bottles and plastic packaging. Examples of plastic packaging include press-through packaging (PTP) packaging, press-through packaging with aluminum laminate film overwrap, strip packaging, SP packaging, plastic bottles, aluminum sachets (including stick packaging), and pouch packaging.
[0031] The present invention will be explained in more detail below with reference to examples and comparative examples, but the present invention is not limited to these examples.
[0032] (Preparation of Pharmaceutical Compositions) (Reference Example 1, Examples 1 to 18, Comparative Examples 1 to 7) Each raw material component of the mixed powder was weighed according to the formulation shown in Table 1, and then uniformly mixed to obtain a preparation.
[0033]
[0034] (Test Examples) <Evaluation Method> For Reference Example 1, Examples 1 to 18, and Comparative Examples 1 to 7, storage stability (change in appearance) was evaluated using the following test method. Storage Stability (Appearance Evaluation) The obtained preparations were stored in a sealed state (airtight container) under 6000 Lx conditions for 14 days, and then the presence or absence of changes in appearance (discoloration) of the samples was visually observed immediately after the start of storage and after 14 days. The degree of appearance change in the present invention was evaluated on a 5-point scale. Evaluation was also performed relative to the evaluation immediately after the start of storage, with 0 (no change) representing no change, 1 (very slight change) representing a very slight discernible change in appearance, 2 (slight change) representing a very slight discernible change in appearance, 3 (change) representing a discernible change, and 4 (significant change) representing a clear discernible change, and the average was calculated. A score of 2 or less was considered acceptable.
[0035] (Results) The results of the storage stability of each product are shown in Table 1. As shown in Table 1, compared to Reference Example 1 containing naproxen, Comparative Example 1 containing naproxen and acetaminophen showed a score of 4.0, confirming that discoloration occurred over time. Furthermore, Examples 1 to 16 containing the components c1 and c2 of the present invention all showed scores of 2 or less, indicating that discoloration was suppressed. On the other hand, Comparative Examples 2 to 5 containing other basic compounds, such as anhydrous calcium hydrogen phosphate, magnesium hydroxide, and synthetic aluminum silicate, showed scores greater than 2, indicating that discoloration was not improved. The results of Comparative Examples 6 and 7 and Examples 17 and 18 revealed that discoloration could be suppressed by adding component (C), even when the amounts of naproxen and acetaminophen added were changed.
[0036] (Formulation Examples) Table 2 shows formulation examples.
[0037]
[0038] According to the present invention, it is possible to provide a pharmaceutical composition containing naproxen or a salt thereof and having excellent storage stability.
Claims
1. A pharmaceutical composition comprising (A) naproxen or a salt thereof, (B) acetaminophen or a salt thereof, and (C) at least one selected from the group consisting of the following (c1) and (c2): (c1) at least one basic compound selected from the group consisting of magnesium silicate, magnesium oxide, magnesium carbonate, synthetic hydrotalcite, aluminum hydroxide gel, and magnesium aluminometasilicate, and (c2) glycine or a salt thereof.
2. The pharmaceutical composition according to claim 1, wherein the content ratio of component (A) to component (B) is 0.125 to 150 parts by mass of component (B) per 1 part by mass of component (A).
3. The pharmaceutical composition according to claim 1 or 2, wherein the content of component (C) is 0.01 to 2 parts by mass per 1 part by mass of the combined content of components (A) and (B).
4. The pharmaceutical composition according to claim 1 or 2, which is a solid formulation.
5. A method for inhibiting discoloration of a pharmaceutical composition containing (A) naproxen or a salt thereof and (B) acetaminophen or a salt thereof, characterized in that the composition contains (C) at least one selected from the group consisting of the following (c1) and (c2): (c1) at least one basic compound selected from the group consisting of magnesium silicate, magnesium oxide, magnesium carbonate, synthetic hydrotalcite, aluminum hydroxide gel, and magnesium aluminometasilicate (c2) glycine or a salt thereof
Citation Information
Patent Citations
Medicinal composition
JP2004123712A
Asthenopia improvement composition
JP2014156458A
Oral solid preparation
JP2017226611A
Tablet and coated tablet and method for producing them
JP2018039801A
Pharmaceutical composition
JP2018076305A
